Patents Assigned to B Cell Design
  • Antibodies against carcinoembryonic antigen for cancer therapy and diagnosis
    Patent number: 11427646
    Abstract: The invention relates to antibodies against carcinoembryonic antigen (CEA) which have a direct cell growth inhibition activity on tumor cells expressing CEA and to their use for the treatment and diagnosis of cancer.
    Type: Grant
    Filed: May 3, 2018
    Date of Patent: August 30, 2022
    Assignee: B CELL DESIGN
    Inventors: Armelle Cuvillier, Gaël Champier
  • Antibodies Against Carcinoembryonic Antigen for Cancer Therapy and Diagnosis
    Publication number: 20200055952
    Abstract: The invention relates to antibodies against carcinoembryonic antigen (CEA) which have a direct cell growth inhibition activity on tumor cells expressing CEA and to their use for the treatment and diagnosis of cancer.
    Type: Application
    Filed: May 3, 2018
    Publication date: February 20, 2020
    Applicant: B Cell Design
    Inventors: Armelle Cuvillier, Gaël Champier
  • Non-HIV vaccine antigen from the vaginal microbiota capable of inducing a mucosal neutralizing protective antibody response against HIV infection
    Patent number: 10273292
    Abstract: A new non-HIV vaccine antigen from Mycoplasma sp. permease capable of inducing a mucosal neutralizing protective antibody response against HIV infection, a neutralizing antibody directed to said antigen, and a method for the identification of new antigens from the mucosal microbiota for the development of vaccines against pathogens.
    Type: Grant
    Filed: February 5, 2015
    Date of Patent: April 30, 2019
    Assignee: B Cell Design SAS
    Inventors: Raphaëlle Claude El Habib, Régis Sodoyer, Armelle Cuvillier, Christiane Moog
  • Transgenic non-human mammal for producing chimeric human immunoglobulin E antibodies
    Patent number: 9872483
    Abstract: The invention relates to a transgenic non-human mammal comprising human immunoglobulin mu and epsilon heavy-chain constant transgenes C? and C? inserted in place of endogenous mu heavy-chain switch sequence S?, and its use for producing chimeric human immunoglobulin E antibodies specific for an antigen of interest.
    Type: Grant
    Filed: July 3, 2014
    Date of Patent: January 23, 2018
    Assignees: B CELL DESIGN, UNIVERSITE DE LIMOGES
    Inventors: Michel Cogne, Brice Laffleur, Armelle Cuvillier, Marie Bosselut
  • Non-HIV Vaccine Antigen from the Vaginal Microbiota Capable of Inducing a Mucosal Neutralizing Protective Antibody Response Against HIV Infection
    Publication number: 20160347828
    Abstract: A new non-HIV vaccine antigen from Mycoplasma sp. permease capable of inducing a mucosal neutralizing protective antibody response against HIV infection, a neutralizing antibody directed to said antigen, and a method for the identification of new antigens from the mucosal microbiota for the development of vaccines against pathogens.
    Type: Application
    Filed: February 5, 2015
    Publication date: December 1, 2016
    Applicant: B CELL DESIGN
    Inventors: Raphaëlle Claude El Habib, Régis Sodoyer, Armelle Cuvillier, Christiane Moog
  • TRANSGENIC NON-HUMAN MAMMAL FOR PRODUCING CHIMERIC HUMAN IMMUNOGLOBULIN E ANTIBODIES
    Publication number: 20160157468
    Abstract: The invention relates to a transgenic non-human mammal comprising human immunoglobulin mu and epsilon heavy-chain constant transgenes C? and C? inserted in place of endogenous mu heavy-chain switch sequence S?, and its use for producing chimeric human immunoglobulin E antibodies specific for an antigen of interest.
    Type: Application
    Filed: July 3, 2014
    Publication date: June 9, 2016
    Applicants: B Cell Design, Université de Limoges
    Inventors: Michel Cogne, Brice Laffleur, Armelle Cuvillier, Marie Bosselut